BioSpace News Archive

The DOL’s Office of Federal Contract Compliance Programs found that AstraZeneca paid a much lower base salary than similar employees to 23 Hispanic female staff and 295 female employees.

There is a noted discrepancy between the price the U.S. government has agreed to pay Merck for the drug and the actual manufacturing costs.

Oncternal Therapeutics, Inc. announced pre-clinical data from ONCT-534, an androgen receptor N-terminal-domain-binding small molecule degrader, was accepted for virtual poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics on October 7-10, 2021.

Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the launch of a strategic initiative that will focus the Company on engineering synthetic biology solutions for a diversified base of customers across an expanded group of end markets including the nutraceutical, cosmeceutical, pharmaceutical, advanced materials, and chemical industries.

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2021 on Thursday, November 4, 2021, prior to the opening of trading on the New York Stock Exchange.

Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”).

EUROIMMUN, a PerkinElmer, Inc. company (NYSE: PKI), announced today that the U.S. Food and Drug Administration has provided Emergency Use Authorization (EUA) for its Anti-SARS-CoV-2 S1 CurveTM ELISA (IgG).

Merit Medical Systems, Inc. (NASDAQ: MMSI), announced today that it will release its financial results for the quarter ended September 30, 2021, after the close of the stock market on Thursday, October 28, 2021.

Takeda Pharmaceutical Company Limited announced that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist.

Endo International plc (NASDAQ: ENDP) will announce its third–quarter 2021 financial results on November 4, 2021 and members of its senior management team will host a conference call and webcast on November 5, 2021 at 7:30am ET before the U.S. financial markets open.